Vinca Alkaloid Toxicity

Overview

4.3 out of 5 (11 Reviews)

Credits

1.00

Post Assessment Questions

6

Start Date

1 Sep 2023

Last Review Date

10 Mar 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Vinca alkaloids, a cell cycle phase M-specific anti-tubulin agent class, have been pivotal in cancer treatment since their early development. Derived from the periwinkle plant (Catharanthus roseus), these alkaloids include first-generation (vincristine, vinblastine), second-generation semi-synthetic derivatives (vinorelbine, vindesine), and the latest addition, vinflunine—known for fluorinated, anti-microtubule properties. Vinflunine stands out with enhanced potency and reduced adverse events, particularly in the context of treating transitional cell urothelial bladder cancer. These medications pose challenges, as toxicity spans multiple organ systems, predominantly manifesting as neurotoxicity, and necessitates vigilance in therapeutic dosing to avoid adverse events, especially with vincristine.

Participants explore the spectrum of vinca alkaloid toxicity, focusing on early recognition and management of adverse effects. Updated insights into dose adjustments, patient-specific risk factors, and tailored interventions are discussed. The role of the interprofessional team, including oncologists, nurses, pharmacists, and therapists, in comprehensive patient care is emphasized. By fostering interdisciplinary collaboration, clinicians enhance patient safety through early detection, tailored interventions, and optimized treatment strategies. Engagement in this course empowers healthcare professionals to recognize and manage vinca alkaloid toxicity effectively. This course ensures clinicians are equipped with the latest knowledge and skills to navigate the complexities of vinca alkaloid therapy, ultimately improving patient care and outcomes in cancer treatment.


Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the signs and symptoms of vinca alkaloid toxicity in patients, including but not limited to neurotoxicity, gastrointestinal effects, and hematological abnormalities.

  • Differentiate between vinca alkaloid toxicity and other causes of toxicity to ensure timely intervention.

  • Assess the severity of vinca alkaloid toxicity through clinical evaluation, laboratory monitoring, and imaging studies if needed.

  • Implement interprofessional collaboration to optimize the management of patients experiencing vinca alkaloid toxicity.

Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Physicians and Physician Associates: StatPearls, LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians and PAs should only claim credit commensurate with the extent of their participation in the activity.

American Board of Anesthesiology: This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in AnesthesiologyTM (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

American Board of Internal Medicine: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology: Successful completion of this Continuing Certification activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Lifelong Learning (CME) credits in the American Board of Pathology’s Continuing Certification Program.

American Board of Pediatrics: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Surgery: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Thoracic Surgery: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment in Practice requirements of the American Board of Thoracic Surgery’s Maintenance of Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.

Royal College of Physicians and Surgeons of Canada: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Christopher C. on 8/12/2021

Morgan P. on 6/29/2022

Marti W. on 7/11/2022

PATIENCE A. on 11/2/2022

Ashley W. on 7/14/2023

Christopher D. on 11/18/2023

Hedy M. on 12/30/2023

Winston S. on 4/25/2024

Clay S. on 7/13/2024

William K. on 8/22/2024

Christine G. on 10/6/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6636 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7880 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$49 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$329 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$499 per 1 year per user